Article
The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.
Daily Derm Times: March 24, 2025
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
“Open Sandwich” Moisturization Regimen Does Not Affect Bioactivity of Retinols and Retinoids
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
New Study Reveals Risk Factors for Persistent Urticaria
ESK-001: A Conversation with Jörn Drappa, MD, PhD, of Alumis on Breakthrough Data and the Future of Psoriasis Treatment